Research and development firm WuXi PharmaTech (Cayman) has signed a definitive merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUnder the deal, WuXi Life Science will acquire WuXi PharmaTech for around $3.3bn in aggregate cash consideration.
WuXi PharmaTech will receive 5.75 per ordinary share and 46 per American depository share (ADS ), representing a 16.5% premium over the closing price of $39.50 per ADS as quoted by the New York Stock Exchange on 29 April.
WuXi Life Science will be owned by a consortium, which comprises affiliates or funds managed or advised by Ally Bridge Group after the consummation of the transactions contemplated by the merger agreement.
WuXi PharmaTech is an open-access R&D capability and technology platform company that provides services to the pharmaceutical, biotechnology and medical device industries.
The firm offers a broad and integrated portfolio of laboratory and manufacturing services across the drug and medical device R&D process.
WuXi has designed the services to enable its global partners in reducing the cycle and lowering the cost of drug and medical device R&D.
The company is also developing a platform to offer clinical diagnostic services directly to physicians and their patients across the globe.
With operations in China and the US, WuXi PharmaTech includes operating subsidiaries in the name of WuXi AppTec.
Subject to shareholder approval and certain other customary closing conditions, the deal is expected to complete in the fourth quarter of this year.
